Oral Ridaforolimus Plus Trastuzumab for Patients With HER2( ) Trastuzumab-Refractory Metastatic Breast Cancer

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F15%3A33155465" target="_blank" >RIV/61989592:15110/15:33155465 - isvavai.cz</a>
Result on the web
<a href="http://dx.doi.org/10.1016/j.clbc.2014.07.008" target="_blank" >http://dx.doi.org/10.1016/j.clbc.2014.07.008</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.clbc.2014.07.008" target="_blank" >10.1016/j.clbc.2014.07.008</a>

Result language
angličtina
Original language name
Oral Ridaforolimus Plus Trastuzumab for Patients With HER2( ) Trastuzumab-Refractory Metastatic Breast Cancer
Original language description
Resistance to trastuzumab treatment is potentially mediated by aberrant phosphatidylinositide 3-kinase (PI3K)/ AKT signaling; ridaforolimus may overcome trastuzumab resistance by inhibiting PI3K signaling. A single-arm phase Ilb trial was conducted to evaluate the efficacy and safety of ridaforolimus-trastuzumab in such resistance in patients with human epidermal growth factor receptor 2 positive (HER2+) trastuzumabrefractory metastatic breast cancer (MBC). The combination showed antitumor activity andmay allow for combination with cytotoxic agents that could increase efficacy.
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FD - Oncology and haematology
OECD FORD branch
—

Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2015
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)